Operating Income: The income after operating expenses.
Protalix BioTherapeutics, Inc. (PLX) had Operating Income of $2.13M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$17.85M |
|
$2.35M |
|
$8.32M |
|
$9.53M |
|
$15.72M |
|
|
Operating Income |
$2.13M |
$0.11M |
|
$2.24M |
|
$2.24M |
|
$2.35M |
|
$2.35M |
|
$2.35M |
|
$2.35M |
|
$2.13M |
|
$2.50M |
|
79.28M |
|
80.81M |
|
$0.03 |
|
$0.03 |
|
| Balance Sheet Financials | |
$66.50M |
|
$4.72M |
|
$15.76M |
|
$82.26M |
|
$21.95M |
|
-- |
|
$7.41M |
|
$29.36M |
|
$52.91M |
|
$52.91M |
|
$52.91M |
|
80.34M |
|
| Cash Flow Statement Financials | |
$-14.02M |
|
$-1.25M |
|
$9.18M |
|
$19.76M |
|
$13.65M |
|
$-6.11M |
|
$1.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
53.37% |
|
11.94% |
|
11.94% |
|
-- |
|
12.54% |
|
13.19% |
|
$-15.26M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
0.39 |
|
1.24 |
|
72.73 |
|
4.45% |
|
4.45% |
|
2.86% |
|
4.45% |
|
$0.66 |
|
$-0.19 |
|
$-0.17 |
|